Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. Among authors: papavassilis c. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB. Papp KA, et al. Among authors: papavassilis c. Br J Dermatol. 2013 Feb;168(2):412-21. doi: 10.1111/bjd.12110. Epub 2013 Jan 18. Br J Dermatol. 2013. PMID: 23106107 Clinical Trial.
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C. Rich P, et al. Among authors: papavassilis c. Br J Dermatol. 2013 Feb;168(2):402-11. doi: 10.1111/bjd.12112. Br J Dermatol. 2013. PMID: 23362969 Clinical Trial.
Item-level psychometric properties for a new patient-reported psoriasis symptom diary.
Strober BE, Nyirady J, Mallya UG, Guettner A, Papavassilis C, Gottlieb AB, Elewski BE, Turner-Bowker DM, Shields AL, Gwaltney CJ, Lebwohl M. Strober BE, et al. Among authors: papavassilis c. Value Health. 2013 Sep-Oct;16(6):1014-22. doi: 10.1016/j.jval.2013.07.002. Value Health. 2013. PMID: 24041351 Free article. Clinical Trial.
Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study.
Sigurgeirsson B, Kircik L, Nemoto O, Mikazans I, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB. Sigurgeirsson B, et al. Among authors: papavassilis c. J Eur Acad Dermatol Venereol. 2014 Aug;28(8):1127-9. doi: 10.1111/jdv.12343. Epub 2013 Dec 13. J Eur Acad Dermatol Venereol. 2014. PMID: 24330415 Clinical Trial. No abstract available.
Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial.
Paul C, Reich K, Gottlieb AB, Mrowietz U, Philipp S, Nakayama J, Harfst E, Guettner A, Papavassilis C; CAIN457A2211 study group. Paul C, et al. Among authors: papavassilis c. J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1670-5. doi: 10.1111/jdv.12359. Epub 2014 Jan 7. J Eur Acad Dermatol Venereol. 2014. PMID: 24393602 Clinical Trial.
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, Guindon C, You R, Papavassilis C; JUNCTURE study group. Paul C, et al. Among authors: papavassilis c. J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90. doi: 10.1111/jdv.12751. Epub 2014 Sep 22. J Eur Acad Dermatol Venereol. 2015. PMID: 25243910 Clinical Trial.
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H; ERASURE Study Japanese subgroup. Ohtsuki M, et al. Among authors: papavassilis c. J Dermatol. 2014 Dec;41(12):1039-46. doi: 10.1111/1346-8138.12668. Epub 2014 Oct 30. J Dermatol. 2014. PMID: 25354738 Clinical Trial.
48 results